Please assess the completion status of the following clinical trial:

Trial Title: A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At completion of Study CL0600-021, subjects will be invited to participate in this trial if they meet the following criteria:~  1. Completion of the 24-month study, CL0600-021, regardless if fully weaned from PN/I.V. support~ 2. Signed and dated informed consent form (ICF) to participate before any study-related procedures of Study TED-C11-001 are performed~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teduglutide (Type: EXPERIMENTAL): 0.05 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).